Rescuing the function of mutant p53 (original) (raw)

• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS Google Scholar
• Finette, B. A., Homans, A. C. & Albertini, R. J. Emergence of genetic instability in children treated for leukemia. Science 288, 514–517 (2000).
  Article CAS Google Scholar
• Komarov, P. G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733–1737 (1999).Traditional cancer therapies are invasive. DNA damage can occur in healthy cells and induce p53-dependent apoptosis. This paper describes an inhibitor of p53 that protects against these effects.
  Article CAS Google Scholar
• Sherr, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60, 3689–3695 (2000).
  CAS Google Scholar
• Hupp, T. R., Lane, D. P. & Ball, K. L. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 352, 1–17 (2000). A recent review highlighting the progress of new approaches to cancer therapy based on restoring the p53 tumour-suppressor pathway.
  Article CAS Google Scholar
• Foster, B. A. et al. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510 (1999).Reports the first screen for prototype pharmacological small molecules that stabilize the native structure of wild-type p53 conformation.
  Article CAS Google Scholar
• Lane, D. P. & Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261–263 (1979).
  Article CAS Google Scholar
• Linzer, D. I. & Levine, A. J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43–52 (1979).
  Article CAS Google Scholar
• Lane, D. P. & Benchimol, S. p53: oncogene or anti-oncogene? Genes Dev. 4, 1–8 (1990).
  Article CAS Google Scholar
• Scheffner, M. et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129–1136 (1990).
  Article CAS Google Scholar
• Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299–303 (1997).
  Article CAS Google Scholar
• Haupt, Y. et al. Mdm2 promotes the rapid degradation of p53. Nature 387, 296–299 (1997).
  Article CAS Google Scholar
• Jones, S. N. et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206–208 (1995).
  Article CAS Google Scholar
• Montes de Oca Luna, R., Wagner, D. S. and Lozano, G. Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53. Nature 378, 203–206 (1995).
  Article CAS Google Scholar
• de Rozieres, S. et al. The loss of Mdm2 induces p53-mediated apoptosis. Oncogene 19, 1691–1697 (2000).
  Article CAS Google Scholar
• Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000).A good general introduction to p53 and its role in tumour suppression.
  CAS Google Scholar
• Nigro, J. M. et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705–708 (1989).
  Article CAS Google Scholar
• Zhang, Y. et al. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl Acad. Sci. USA 97, 6427–6432 (2000).
  Article CAS Google Scholar
• Hainaut, P. & Hollstein, M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77, 81–137 (2000).
  Article CAS Google Scholar
• Cho, Y. et al. Crystal structure of a p53 tumor suppressor–DNA complex: understanding tumorigenic mutations. Science 265, 346–355 (1994).Presents the first crystal structure of p53 core domain. The location and structural consequences of hot-spot TP53 mutations are discussed.
  Article CAS Google Scholar
• Milner, J. Flexibility: the key to p53 function? Trends Biochem. Sci. 20, 49–51 (1995).
  Article CAS Google Scholar
• Rolley, N., Butcher, S. & Milner, J. Specific DNA binding by different classes of human p53 mutants. Oncogene 11, 763–770 (1995).
  CAS PubMed Google Scholar
• el-Deiry, W. S. et al. Definition of a consensus binding site for p53. Nature Genet. 1, 45–49 (1992).
  Article CAS Google Scholar
• Pavletich, N. P., Chambers, K. A. & Pabo, C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7, 2556–2564 (1993).
  Article CAS Google Scholar
• Cohen, P. A. et al. Biochemical characterization of different conformational states of the Sf9 cell-purified p53 His175 mutant protein. FEBS Lett. 463, 179–184 (1999).
  Article CAS Google Scholar
• Hansen, S., Hupp, T. R. & Lane, D. P. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group. J. Biol. Chem. 271, 3917–3924 (1996).
  Article CAS Google Scholar
• Bullock, A. N. et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl Acad. Sci. USA 94, 14338–14342 (1997).
  Article CAS Google Scholar
• Bullock, A. N., Henckel, J. & Fersht, A. R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245–1256 (2000).Mutants of p53 are shown to have a wide range of stabilities and DNA-binding affinities. The mutant conformation is redefined as five mutant classes of differing severity that correlate with the site of mutation.
  Article CAS Google Scholar
• Wong, K. B. et al. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl Acad. Sci. USA 96, 8438–8442 (1999).
  Article CAS Google Scholar
• Wieczorek, A. M. et al. Structure-based rescue of common tumor-derived p53 mutants. Nature Med. 2, 1143–1146 (1996).
  Article CAS Google Scholar
• Brachmann, R. K. et al. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17, 1847–1859 (1998).Second-site mutations are reported that rescue structural mutants of p53. Their action provides a model for small molecule drug therapy.
  Article CAS Google Scholar
• Nikolova, P. V. et al. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19, 370–378 (2000).The effect of suppressor mutations is characterized by stability, DNA binding and NMR studies.
  Article CAS Google Scholar
• Nikolova, P. V. et al. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc. Natl Acad. Sci. USA 95, 14675–14680 (1998).
  Article CAS Google Scholar
• Milner, J. & Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765–774 (1991).
  Article CAS Google Scholar
• Zhao, K. et al. Crystal structure of the mouse p53 core DNA-binding domain at 2.7 Å resolution. J. Biol. Chem. 276, 12120–12127 (2001).
  Article CAS Google Scholar
• Shaulian, E. et al. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell Biol. 12, 5581–5592 (1992).
  Article CAS Google Scholar
• Chene, P. In vitro analysis of the dominant negative effect of p53 mutants. J. Mol. Biol. 281, 205–209 (1998).
  Article CAS Google Scholar
• Nielsen, L. L. & Maneval, D. C. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 5, 52–63 (1998).
  CAS PubMed Google Scholar
• Ghaneh, P. et al. Adenovirus-mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther. 8, 199–208 (2001).
  Article CAS Google Scholar
• Mateu, M. G. & Fersht, A. R. Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. Proc. Natl Acad. Sci. USA 96, 3595–3599 (1999).
  Article CAS Google Scholar
• Stavridi, E. S. et al. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions. Protein Sci. 8, 1773–1779 (1999).
  Article CAS Google Scholar
• Hupp, T. R. & Lane, D. P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4, 865–875 (1994).
  Article CAS Google Scholar
• Anderson, M. E. et al. Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation. Mol. Cell Biol. 17, 6255–6264 (1997).
  Article CAS Google Scholar
• Kim, A. L. et al. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J. Biol. Chem. 274, 34924–34931 (1999).
  Article CAS Google Scholar
• Hupp, T. R., Sparks, A. & Lane, D. P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83, 237–245 (1995).
  Article CAS Google Scholar
• Selivanova, G. et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med. 3, 632–638 (1997).
  Article CAS Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
  Article CAS Google Scholar
• Hupp, T. R. Regulation of p53 protein function through alterations in protein-folding pathways. Cell. Mol. Life Sci. 55, 88–95 (1999).
  Article CAS Google Scholar
• Giannakakou, P. et al. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nature Cell Biol. 2, 709–717 (2000).
  Article CAS Google Scholar
• Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293, 876–880 (2001).
  Article CAS Google Scholar
• Stoll, R. et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40, 336–344 (2001).
  Article CAS Google Scholar
• Grüschow, S. et al. Isolation and structure elucidation of chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 123, 554–560 (2001).
  Article Google Scholar
• Hietanen, S. et al. Activation of p53 in cervical carcinoma cells by small molecules. Proc. Natl Acad. Sci. USA 97, 8501–8506 (2000).
  Article CAS Google Scholar
• McCormick, F. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin. Cancer Biol. 10, 453–459 (2000).
  Article CAS Google Scholar
• Gibbs, J. B. Mechanism-based target identification and drug discovery in cancer research. Science 287, 1969–1973 (2000).
  Article CAS Google Scholar
• Dewson, G. Small, but deadly: small-molecule inhibition of Bcl-2 homologue heterodimerization. Trends Biochem. Sci. 26, 218–219 (2001).
  Article CAS Google Scholar
• Sigal, A. & Rotter, V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60, 6788–6793 (2000).
  CAS Google Scholar
• Gaiddon, C. et al. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell Biol. 21, 1874–1887 (2001).
  Article CAS Google Scholar
• Strano, S. et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275, 29503–29512 (2000).
  Article CAS Google Scholar
• Koga, H. & Deppert, W. Identification of genomic DNA sequences bound by mutant p53 protein (Gly245→Ser) in vivo. Oncogene 19, 4178–4183 (2000).
  Article CAS Google Scholar
• Deppert, W. Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions. J. Cell Biochem. 62, 172–180 (1996).
  Article CAS Google Scholar
• Guo, A. et al. The function of PML in p53-dependent apoptosis. Nature Cell. Biol. 2, 730–736 (2000).
  Article CAS Google Scholar
• Fogal, V. et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19, 6185–6195 (2000).
  Article CAS Google Scholar
• Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948–953 (1996).
  Article CAS Google Scholar
• Jeffrey, P. D., Gorina, S. & Pavletich, N. P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267, 1498–1502 (1995).
  Article CAS Google Scholar
• Clore, G. M. et al. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nature Struct. Biol. 2, 321–333 (1995).
  Article CAS Google Scholar
• Lee, W. et al. Solution structure of the tetrameric minimum transforming domain of p53. Nature Struct. Biol. 1, 877–890 (1994).
  Article CAS Google Scholar
• Rustandi, R. R., Baldisseri, D. M. & Weber, D. J. Structure of the negative regulatory domain of p53 bound to S100B (betabeta). Nature Struct. Biol. 7, 570–574 (2000).
  Article CAS Google Scholar
• Koradi, R., Billeter, M. & Wuthrich, K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14, 29–32, 51–5 (1996).
  Article Google Scholar
• Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11, 281–296 (1991).
  Article CAS Google Scholar